Pavlos Msaouel

3 weeks ago | cell.com | Zilong Zhao |Benxia Hu |Yalan Deng |Melinda Soeung |Jun Yao |Lanxin Bei | +25 more

Keywords sickle cell disease renal medullary carcinoma ferroptosis genomic architecture alteration Hi-C H2S SLC7A11 SMARCB1 immune checkpoint inhibitors CD8+ T cells Introduction Sickle cell disease (SCD), the most prevalent inherited blood disorder,1 arises from the homozygous HbS mutation (GAG>GTG: βGlu6Val), causing hemoglobin abnormalities that make red blood cells (RBCs) assume a sickle or crescent shape.2 Individuals with SCD have RBCs prone to hemolysis, leading to vaso-occlusive...

3 weeks ago | cell.com | Zilong Zhao |Benxia Hu |Yalan Deng |Melinda Soeung |Jun Yao |Lanxin Bei | +25 more

Keywords sickle cell disease renal medullary carcinoma ferroptosis genomic architecture alteration Hi-C H2S SLC7A11 SMARCB1 immune checkpoint inhibitors CD8+ T cells Introduction Sickle cell disease (SCD), the most prevalent inherited blood disorder,1 arises from the homozygous HbS mutation (GAG>GTG: βGlu6Val), causing hemoglobin abnormalities that make red blood cells (RBCs) assume a sickle or crescent shape.2 Individuals with SCD have RBCs prone to hemolysis, leading to vaso-occlusive...

Jan 9, 2025 | nature.com | Pavlos Msaouel |Rahul Sheth |Amishi Y. Shah |Amado J. Zurita |Giannicola Genovese |Minghao Dang | +3 more

AbstractWe conducted a phase I trial to determine the optimal dose of triplet therapy with the tyrosine kinase inhibitor sitravatinib plus nivolumab plus ipilimumab in 22 previously untreated patients with advanced clear cell renal cell carcinoma. The primary endpoint was safety.

Sep 6, 2024 | digitalcommons.library.tmc.edu | Jose A. Karam |Pavlos Msaouel |Cara Haymaker |Surena F. Matin

Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in combination with nivolumab in patients with locally advanced clear cell renal cell carcinoma (ccRCC) prior to curative nephrectomy (NCT03680521).

Jul 27, 2024 | cancernetwork.com | Pavlos Msaouel

Ubamatamab in combination with anti-PD-inhibition may enhance the immune response in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma, said Pavlos Msaouel, MD, PhD.